Company profile
Medicus Pharma Ltd. Common Stock
NASDAQ: MDCX · Healthcare · Biotechnology
Canadian filerHQ W. Conshohocken, CIK 0001997296Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 14DQ —GM —SS 27
v0.1 · 35/100 weight · pillars only
↑ filing timeliness, market scale · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$47.3M
Employees
16
as of 2026-08-22
Market cap
$6.0M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$47.3M-$47.3M2025
Operating income-$34.4M-$34.4M2025
Total assets$10.1M$10.1M2025
Liabilities$10.0M$10.0M2025
Equity-$67.6k-$67.6k2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Medicus Pharma Ltd. Common Stock’s financial profile?
Medicus Pharma Ltd. Common Stock earned -$47.3M in FY2025 net income.
Peers · Healthcare
Eastgate Biotech Corp.——CYduct Diagnostics, Inc.——Reviva Pharmaceuticals Holdings, Inc.——Adial Pharmaceuticals, Inc.——Alzamend Neuro Inc——Cadrenal Therapeutics, Inc. Common Stock——Key facts
CEORaza Bokhari
SectorHealthcare
IndustryBiotechnology
HeadquartersW. Conshohocken, null
ExchangeNASDAQ: MDCX
Employees16
IPO date2024-11-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.